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a b s t r a c t
Interferon-alpha (IFNα) can effectively inhibit or abort a viral infection within the host. It has been
reported that IFN induction and production is hindered during classical swine fever virus (CSFV)
infection. Most of those studies have been performed in vitro, making it difﬁcult to elucidate the actual
role of IFNs during CSFV infection in swine. Here, we report the effect of IFNα treatment (delivered by a
replication defective recombinant human adenovirus type 5, Ad5) in swine experimentally infected with
highly virulent CSFV strain Brescia. Treatment with two different subtypes of IFNα delayed the
appearance of CSF-related clinical signs and virus replication although it did not prevent lethal disease.
This is the ﬁrst report describing the effect of IFNα treatment during CSFV infection in swine.
Published by Elsevier Inc.
Introduction
Classical swine fever (CSF) is an economically signiﬁcant, highly
contagious swine disease. The etiological agent, CSF virus (CSFV), is
an enveloped virus with a positive-sense, single-stranded RNA
genome, classiﬁed as a member of the genus Pestivirus within the
family Flaviviridae (Becher et al., 2003). The 12.5 kb CSFV genome
contains a single open reading frame that encodes a 3898-amino
acid polyprotein and ultimately yields 11–12 ﬁnal cleavage products
(NH2-Npro-C-Erns-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-
COOH) through co- and post-translational processing of the poly-
protein by cellular and viral proteases (Leifer et al., 2013).
Prophylactic vaccination with live attenuated viruses (LAVs) can
induce effective protection against CSF, often earlier than protection
afforded by the adaptive immune response (van Oirschot, 2003);
however, the host mechanisms mediating this innate response
remain unknown.
The ability of the host's innate immune system to interact with
CSFV replication has been studied in vitro by several groups
(Bensaude et al., 2004; Choi et al., 2004; Dong et al., 2013;
Fernandez-Sainz et al., 2010), and included evaluation of the
inhibitory effects induced by Mx1 (He et al., 2014) and MxA
proteins (Zhao et al., 2011) as well as by IFN-α and IFN-γ
(Graham et al., 2012; Xia et al., 2005). It has been reported that
CSFV possesses mechanisms that hinder the induction and pro-
duction of IFNs during infection. This inhibitory effect has been
associated with two viral proteins, Npro and Erns. For instance, the
dsRNA-binding and RNase activities of pestivirus Erns has been
shown to inhibit IFN synthesis induced by extracellular dsRNA
(Magkouras et al., 2008) and/or pestiviral single- and double-
stranded RNAs (Iqbal et al., 2004; Luo et al., 2009; Mätzener et al.,
2009). In addition, IFN regulatory factor 7 (IRF7) is deregulated by
directly interacting with CSFV Npro, thus inhibiting the production
of IFNα and decreasing the anti-viral cellular response (Fiebach et
al., 2011). Also, Npro promotes proteosomal degradation of IFN
regulatory factor 3 (IRF3) (Bauhofer et al., 2007; La Rocca et al.,
2005; Seago et al., 2007) and recombinant CSFV lacking Npro is
attenuated in swine (Mayer et al., 2004). However, replacement of
Npro in a virulent CSFV strain by the corresponding gene of an
attenuated strain does not diminish the virulent phenotype
(Mayer et al., 2004). Moreover, recombinant viruses, developed
from a highly virulent parental virus, harboring Npro mutations
abrogating the ability to degrade IRF3 and thus preventing IFN-α/β
induction were not attenuated in swine (Ruggli et al., 2009).
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Therefore, the actual role of IFN during CSFV infection in swine is
poorly understood.
Here, we report the effect of IFNα treatment (delivered by
a replication defective human adenovirus type 5, Ad5) on the
course of experimental infection of swine infected with the
highly virulent CSFV Brescia strain. Our results show that IFNα
treatment signiﬁcantly delays the appearance of CSF disease and
systemic virus replication. To our knowledge, this is the ﬁrst
report describing the effect of IFN-α during CSFV infection
in swine.
Results
Anti-CSFV activity of swine IFNα
Similar to other mammals, the swine genome encodes for
several IFN genes (Cheng et al., 2006; Sang et al., 2010). The anti-
viral effect of 18 swine IFNα genes was assessed in CSFV-infected
cultures. IBRS2 cells were transfected with the same amount of
individual plasmids representing each of the 18 swine IFNα genes
described in Material and methods. IFNs produced in the super-
natant of the transfected cell cultures were harvested and assessed
for their anti-CSFV activity in primary cell cultures of fetal porcine
kidney (EPK). A wide range, from 3 to 10 logn, of anti-viral activity
was observed depending on the subtype of IFNα tested (Fig. 1). The
subtype IFNα-D2 exhibited the greatest activity (9 log 2 U/ml) and
therefore it was selected to be cloned in the recombinant replica-
tion defective Ad5 vector for further studies.
Development of a recombinant Ad5 expressing swine IFNα
It had been reported that an Ad5 expressing pIFNα (Ad5-
pIFNα-MG) effectively controls foot- and-mouth disease (FMD)
in swine (Chinsangaram et al., 2003; Moraes et al., 2001, 2003).
The clone IFNα-D2 was therefore selected and expressed using the
same Ad5 vector (Ad5-Blue). Recombinant Ad5-pIFNα-MG and
Ad5-pIFNα-D2 were used to infect IBRS2 cells and supernatants
containing secreted proteins were analyzed for the presence of IFN
protein and antiviral activity. Quantiﬁcation was performed using
an in-house developed ELISA as previously described (Moraes et
al., 2003). While IFNα-MG was produced at a concentration of
6.59 μg/ml (SD¼0.205), IFNα-D2 was produced at 4.45 μg/ml
(SD¼0.262) (Fig. 2A). These preparations consistently exhibited
similar antiviral activity against CSFV (7.09 log2 IU/ml) and VSV
(11.54 log2 IU/ml) (data not shown). Western blot analysis
suggested that IFNα-MG had a signiﬁcantly higher MW compared
to IFNα-D2; however, treatment of the secreted proteins with a
mix of deglycosylases (PDM) indicated that the heterogeneity in
MW was mainly due to glycosylation. While IFNα–MG displayed a
signiﬁcant shift in its electrophoretic mobility, IFNα-D2 appeared
unchanged after PDM treatment (Fig. 2B).
Effect of Ad5-pIFNα on the course of disease in animals
experimentally infected with virulent CSFV Brescia strain.
The possible protective role of swine IFNα on the course of
infection was assessed in susceptible animals treated with recombi-
nant Ad5 viruses expressing each of the IFNα, and experimentally
infected with virulent CSFV Brescia. Three groups of 30–40 pound
pigs were SC inoculated, one day prior to CSFV infection, with 1010 pfu
of either Ad5-pIFNα-MG or Ad5-pIFNα-D2, while a third group
received the same dose of the empty vector, Ad5-Blue, as a control.
Twenty-four hours later animals were intranasally infected with 105
TCID50 of CSFV Brescia. Animals were monitored daily for increases in
body temperature and the appearance of CSF-related clinical signs.
Detection and characterization of IFNα in serum of inoculated
animals was determined by three methodologies: the IFN-
dependent CAT assay in cells harboring the MxCAT reporter
construct (Fray et al. 2001), in-house sandwich ELISA (Moraes
et al., 2003), and by quantifying the anti-viral activity in cell
cultures infected with VSV (Rubinstein et al. 1981).
Results, detected by the MxCAT assay (Fig. 3A), demonstrated
that by 24 h postinoculation all animals treated with Ad5-pIFNα had
signiﬁcant levels of IFN activity in sera. Swine treated with Ad5-
pIFNα-D2 displayed an average of 393.06752.72 IU/ml while ani-
mals treated with Ad5-pIFNα-MG had signiﬁcantly higher levels,
674.347103.44 IU/ml. As expected, control animals inoculated with
Ad5-Blue did not develop an IFN response one day after treatment.
The differences in IFN levels observed using the MxCAT ELISA at
the time of CSFV challenge (0 dpc) in animals receiving Ad5-pIFNα-
D2 or Ad5-pIFNα-MG were not detected when IFN levels were
assayed with either anti-VSV replication or a quantitative IFN ELISA.
Anti-VSV activity at 1 dpi in sera of animals inoculated with Ad5-
pIFNα-D2 (average¼5.94 log2 IU/ml; SD¼0.35) did not signiﬁcantly
differ from those inoculated with Ad5-pIFNα-MG (average¼5.77
log2 IU/ml; SD¼0) (Fig. 3B). Similarly, levels of IFNα protein in
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Fig. 1. Anti-CSFV activity of different swine IFNα genes transiently expressed in
IBRS2 cells. Activity is detected in EPK cells pretreated with the different IFNα
preparations and infected with CSFV Brescia strain (BICv). Control is an Ad5-pIFNα–
MG derived IFN-α preparation. Asterisk on the top the bar indicates statistical
signiﬁcance compared with preparation D2 (T-test po0.01).
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Fig. 2. Expression of swine IFNα in recombinant Ad5-pIFNα. Analysis by
(A) quantitative ELISA and (B) Western blot of untreated (lanes 1 and 3) and
PNGase treated (lanes 2 and 4) Ad5-pIFNα–D2 (lanes 1 and 2) and Ad5-pIFNα–MG
(lanes 3 and 4) derived semi-puriﬁed IFNα preparations. Lane 5 contains Ad5-Blue.
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serum, detected by sandwich ELISA, in animals treated with Ad5-
pIFNα-MG were slightly higher (average¼20,708 pg/ml; SD¼1,201
than those of animals receiving Ad5-pIFNα-D2 (avera-
ge¼18,999 pg/ml; SD¼846.19) (Fig. 3C).
In summary, three independent methodologies indicated that by
24 h post-infection with either Ad5-pIFNα construct, animals devel-
oped a signiﬁcant IFNα response that was easily detected in sera.
A proﬁle of serum IFNα concentration covering the complete
experimental period demonstrated that IFN levels signiﬁcantly
increased by 24 h post-Ad5-IFNα inoculation (consistently with
the expected expression from the Ad5 vector) followed by a
progressive decreased to undetectable levels in most of the
animals by day 5 pi. In addition, a new peak appeared in most
animals following challenge with CSFV and concurrent with the
development of disease and viremia in those animals (Fig. 4).
Our in vivo study examined the effects of Ad5-pIFNα in animals
challenged with virulent CSFV Brescia. Ad5-Blue-treated animals
challenged with this virulent CSFV strain developed anorexia,
depression and fever by 5 days post-challenge (dpc) (Figs. 5A
and B and Table 1) and, with the exception of one animal that died
at 5 dpc, the other four died or were euthanized in extremis by 8–9
dpc, exhibiting typical signs of CSF (Table 1). In the group of
animals receiving Ad5-pIFNα–D2, one animal was found dead at
4 dpc; however, CSF-related signs were absent and no virus was
isolated from blood samples suggesting that this animal died from
a non-CSF related cause. Of the other four animals, one presented a
persistent rise in body temperature and progressive worsening of
CSF-related signs that lead to euthanasia by 12 dpc. The other
three animals presented delayed clinical disease by 11–12 dpc,
dying or being euthanized by 14 dpc (Table 1 and Fig. 5). Inter-
estingly, all animals treated with Ad5-pIFNα-MG displayed
delayed disease. Pigs remained clinically normal until 14–15 dpc,
but then disease progressed for 3–5 days and animals died or were
humanely euthanized (Table 1). In summary, treatment with
either Ad5-pIFNα signiﬁcantly delayed both, the appearance
of clinical signs (by 4 and 9 days in animals treated with
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Fig. 3. Levels of IFNα at the time of challenge with CSFV BICv in sera of animals
inoculated 24 h earlier with Ad5-pIFNα–D2 or Ad5-pIFNα–MG. IFN levels were
detected by (A) MxCAT ELISA, (B) anti-VSV replication activity and (C) quantitative
sandwich ELISA. 0 and 1 dpi refer day postinoculation with Ad5-pIFNα–D2 or Ad5-
pIFNα–MG.
Fig. 4. Time course IFNα levels during swine experiment. IFNα levels in serumwere
measured by ELISA, as described in Materials and methods, prior to Ad5 inoculation
(1 dpc), at day 1 postAd5 inoculation (0 dpc), and at different times postCSFV
challenge (4–18 dpc). Each curve in each of the panels represents one individual
within a particular group. Results are expressed as pg IFNα/ml of serum.
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Ad5-pIFNα-D2 and Ad5-pIFNα-MG, respectively) as well as the
time of death (by 6 and 10 days in animals treated with Ad5-
pIFNα-D2 and Ad5-pIFNα-MG, respectively) when compared to
animals receiving the control vector, Ad5-Blue. These differences
were more evident in animals receiving Ad5-pIFNα-MG.
Viremia in Ad5-treated animals challenged with virulent CSFV was
examined at 4, 7, 11, 14 and 21 dpc. Quantitation of virus in blood was
performed using SK6 cells and infected cells were detected by
immuno-cytochemistry using WH303, a mAb that reacts speciﬁcally
with the CSFV structural glycoprotein E2. As expected, in Ad5-Blue-
treated control animals, viremia was observed within 4 dpc, with
virus titers remaining high (107 TCID50/ml) at 7 dpc, the last time
point tested before animals died or were euthanized (Fig. 6). Animals
pretreated with Ad5-pIFNα-D2 presented a prolonged viremia, ﬁrst
detected at 4 dpc (104 TCID50/ml), that progressively increased until
the last day of sampling (107 TCID50/ml by 14 dpi) before being
euthanized. Interestingly, although animals pretreated with Ad5-
pIFNα-MG also displayed a lengthened viremia compared to those
treated with Ad5-Blue, titers only reached 102 TCID50/ml by 4 dpc,
and remained at similar levels until 11 dpc. Similarly to the group
treated with Ad5-pIFNα-D2, viremia increased by 14 dpc reaching
maximum titers at the time the animals were euthanized (14–19
dpc). However, the titers were signiﬁcantly lower than animals
treated with Ad5-pIFNα-D2 throughout the experiment until 14
dpc, when they increased to similar levels.
It has been previously reported that a hallmark of acute CSFV
infection is the high IFNα levels found in the serum after infection
(Summerﬁeld et al., 2006). Consistently, a peak of IFN was
detected by 4 days post-challenge in all control animals when
clinical signs of CSF became evident (data not shown). Interest-
ingly, all animals treated with Ad5-pIFNα that showed a delay in
the clinical onset of disease also showed a delay in the induction of
IFNα as a consequence of the infection (data not shown).
In summary, our results indicated that pretreatment with Ad5-
pIFNα delayed the development of viremia and the appearance of
CSF clinical disease. However, regardless of treatment, all animals
developed disease and died or were euthanized.
Discussion
Most CSFV live attenuated vaccines provide protection within
one week of administration, suggesting that protection is mediated
by the host innate immune response (Graham et al., 2012; van
Oirschot, 2003). There are no studies deﬁning the role of IFN in
mediating protection against the progress of infection in swine.
Virulence studies using recombinant CSFV harboring modiﬁed
forms of Npro, which should alter IFN induction/production ren-
dered controversial results (Mayer et al., 2004; Ruggli et al., 2009;
Tamura et al., 2014). Interestingly, a direct correlation between the
virulence of a CSFV strain and the amount of IFN produced during
the infection in swine has been reported (Renson et al., 2010;
Summerﬁeld et al., 1998; Tarradas et al., 2014), challenging the
hypothesis that inhibition of host IFN is a critical step during
infection, particularly with highly virulent CSFV strains. More
recently, Tamura et al. (2014) have shown that functional Npro
inﬂuences the innate immune response at local sites of virus
replication in pigs thus contributing to pathogenicity in synergy
with viral replication. In the current work we also observed that
progression of disease correlated with an increase in the levels of
Table 1
Survival and fever response in animals pretreated with Ad5-pIFNα after challenge with virulent CSFV Brescia.
Challenge group Fever
Mean time to death, days(7SD) No. of days to onset (7SD) Duration, No. of days (7SD) Maximum daily temp, 1F (7SD)
Ad5-pIFNα–MG 17.6 (1.5) 14.8 (0.4) 2.8 (1. 1) 106.16 (2.80)
Ad5-pIFNα–D2 13.5 (1) 9.5 (3.7) 4 (2.7) 106.32 (0.22)
Ad5-Blue 7.8 (1.6) 5 (0) 2.8 (1.6) 105.62 (0.99)
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Fig. 5. Morbidity (A) and mortality (B) in animals pretreated with Ad5-pIFNα-D2,
Ad5-pIFNα-MG or Ad5-Blue (control) and challenged with BICv.
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endogenous IFN after challenge. In the control animals, treated with
Ad5-Blue, the peak of endogenous IFN was detected at 4 dpc when
clinical signs of disease appeared. However, endogenous IFN was
not detectable in any of the animals treated with Ad5-poIFNα until
days 7–11 post-challenge. Consistent with our previous studies
(Chinsangaram et al., 2003; Moraes et al., 2003), IFN induced by
Ad5-pIFNα reached maximum levels by day 1 post-infection and
totally disappeared by day 4. These results suggested that there was
no overlap between the IFN response induced by the Ad5-pIFNα
and the one induced by CSFV infection.
Our results suggest that pretreatment with Ad5-pIFNα affects
the course of CSF in infected animals. Although animals do not
survive the infection, disease is delayed when compared to control
animals that were not treated with IFN-α. While all Ad5-Blue-
treated animals developed clinical signs of CSF by 5 dpc, three of
the ﬁve animals treated with Ad5-pIFNα-D2 did not develop
symptoms until 9 dpc and most animals treated with Ad5-
pIFNα-MG did not show signs of disease until 15 dpc. All Ad5-
Blue-treated animals died or were euthanized by 9 dpc, but most
of the Ad5-pIFNα-D2 and Ad5-pIFNα-MG-treated animals sur-
vived until 14 dpc and 18 dpc, respectively. Analysis of the viremia
in animals from the different groups indicates that ﬁnal titers were
similar among all groups. However, the presence of IFN in serum at
the moment of challenge inﬂuenced the progression of viremia,
since initial CSFV titers in IFN-treated animals were much lower
than the control group and these low levels were maintained for
11–14 dpc depending on the Ad5-pIFNα treatment. IFNα response,
as detected in serum of animals treated with Ad5-pIFNα-MG, is
present at 24 h pi and almost completely disappeared by the 4th
day (Moraes et al., 2003). It is possible that the slight difference in
the response induced by either IFNα was due to the differential
glycosylation pattern. Ceaglio et al. (2010) have proposed that
IFNα glycosylation affects the stability of IFN in serum; however,
our experimental data suggests that differences are not signiﬁcant,
at least when challenge is performed 24 h post-Ad5 inoculation.
The understanding of the role of IFN glycosylation in anti CSFV
activity in vivo is beyond the scope of this study. Results suggest
that administration of IFNα reduced the early development of
viremia, but ultimately did not change the lethal outcome of the
disease. Additional studies examining whether more sustained
levels of IFN could ultimately control virus replication and there-
fore protect animals against CSFV is warranted. It is important to
mention that pretreatment of swine with Ad5-pIFNα-MG follow-
ing the same protocol has protected swine from challenge with
highly virulent strains of multiple serotypes of FMD virus (FMDV)
(Chinsangaram et al., 2003; Moraes et al., 2001, 2003; Dias et al.
2011). It has been reported that although the production of IFN is
the ﬁrst barrier against viral replication within the host, the
speciﬁc dynamics of each infection determines the overall out-
come. In fact, high viremia during CSFV infection in swine or
FMDV infection in cattle correlates with lymphopenia and high
levels of systemic IFN, although IFN cannot exert its protective
functions (Summerﬁeld et al., 2006; Perez-Martin et al., 2012).
Establishment of a robust antiviral state, both systemic and
localized to the site(s) of primary virus replication, seems to be
crucial to preventing virus replication and spread. To our knowl-
edge, this is the ﬁrst report demonstrating the protective role of
IFNα during the infection of swine with CSFV.
Materials and methods
Viruses, antibodies and cells
BVDV-free swine kidney cells (SK6) (Terpstra et al., 1990) were
cultured in Dulbecco's Minimal Essential Medium (DMEM) (Gibco,
Grand Island, NY) with 10% fetal calf serum (FCS) (Atlas Biologicals,
Fort Collins, CO). HEK-293 cells (ATCC CRL-1573) were obtained
from the American Type Culture Collection (ATCC, Rockville, MD).
Porcine kidney IBRS2 and primary embryonic porcine kidney (EPK)
cells were obtained from the Foreign Animal Disease Diagnostic
Laboratory (FADDL) at Plum Island Animal Disease Center (PIADC),
Greenport, NY. Madin-Darby Bovine Kidney Epithelial cells, MDBK-
t2 cells, transfected with a plasmid expressing the human MxA
promoter linked to a chloramphenicol acetyltransferase (CAT)
reporter gene (MDBK-t2) (Fray et al., 2001; Ronni et al., 1998)
were kindly provided by B. Charleston (Institute for Animal Health,
Pirbright, UK). IBRS2, MDBK-t2 and HEK-293 cell lines were
maintained in Eagle's Minimal Essential Medium (MEM) contain-
ing 10% fetal bovine serum (FBS) supplemented with antibiotics,
glutamine and non-essential amino acids. For MDBK-t2, the media
was also supplemented with 10 mg/ml blasticidin (Invitrogen,
Carlsbad, CA). All incubations were performed at 37 1C with 5%
CO2 unless otherwise stated.
CSFV BICv, a virus derived from the Brescia strain infectious
clone (Risatti et al., 2005a), was propagated in SK6 cells. Titrations
of CSFV from clinical samples were performed using SK6 cells
seeded in 96-well plates (Costar, Cambridge, MA). After 4 days in
culture, viral infectivity was detected by an immunoperoxidase
assay using the CSFV monoclonal antibody mAb WH303 (Edwards
et al., 1991) and the Vectastain ABC kit (Vector Laboratories,
Burlingame, CA). Titers were calculated using the method of Reed
and Muench (Reed and Muench, 1938) and expressed as TCID50/
ml. As performed, test sensitivity was 41.8 TCID50/ml.
Vesicular stomatitis virus (VSV) serotype New Jersey (NJ0612NME6)
was kindly provided by Dr. L. Rodriguez (Plum Island Animal Disease
Center, NY).
Expression of IFNα
DNA from 18 porcine IFN-α genes (NM_001166311-A1; GQ4-
15056-A2; XM_003480495-A3; NM_001166319-A4; NM_0011-
64860-A5; XM_003353504-B1; XM_003480504-B2; XM_00348-
0507-B3; XM_003480505-B4; NM_001195375-B5; XM_003353-
507-B6; NM_001164855-C1; XM_003121882-C2; GQ415060-C3;
GQ415061-C4; XM_005660067-C5; DQ872659-D1; GQ415066-
D2) was synthesized by Genscript USA, Inc. (Piscataway, NJ). These
DNA sequences were sub-cloned into a pcDNA3.1() plasmid (Life
Technologies, Frederick, MD) between the NheI and NotI restric-
tion sites. Plasmid DNA containing the inserts as well as the
vector-only control were transiently transfected into IBRS2 cells
for synthesis of each IFN-α protein using Lipofectamine 2000 (Life
Technologies) according to the manufacturer's instructions. Brieﬂy,
0.8 mg of each plasmid DNA was mixed with 2 μl of Lipofectamine
2000 in Opti-MEM (Life Technologies) and incubated for 20 min at
room temperature. The plasmid DNA-Lipofectamine mixtures
were added to fully conﬂuent cell monolayers in a 24-well tissue
culture plate and the cells were incubated for 3 h. After the 3 h
incubation, the media was replaced with 500 ml of growth medium
containing 5% FBS. The cell culture supernatants were harvested
2 days post-transfection and stored at 15 1C to 25 1C until used
in antiviral assays.
Expression of IFNα using a replication defective human Ad5 vector
Two recombinant Ad5 vectors derived from Ad5 Blue (Moraes
et al., 2001) were used to express IFN in swine. One of them, Ad5-
pIFNα, had been previously tested against FMD (Chinsangaram
et al., 2003). An additional clone was constructed using the IFN
sequence of GenBank Accession no X57191 (Ad5-pIFNα-D2). Both
Ad5-pIFNα constructs were plaque-isolated and propagated in
HEK 293 cells, puriﬁed twice by CsCl gradient centrifugation and
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titrated using the Reed and Muench (1938). Ad5-pIFNα titers were
calculated in plaque forming units (pfu), as 10X0.7, where 10X
corresponded to the experimentally determined TCID50/ml titers.
To measure IFN-α protein expression, IBRS2 cells were infe-
cted with each Ad5-pIFNα at MOI¼20 pfu/cell and incubated for
24 h. Cell supernatants were then collected and ﬁltered using
Centricons 30 ﬁlters (Millipore, Billerica, MA). When indicated,
supernatants were treated to remove N- and O-linked glycans
with Protein Deglycosylation Mix (PDM, New England Biolabs,
Ipswich, MA) following the manufacturer's directions. Proteins
present in the ﬁltered supernatants were resolved by SDS-PAGE
and detected by immunoblotting using a polyclonal antibody
obtained at PIADC by inoculating rabbits with Escherichia coli-
expressed porcine IFN-α recombinant protein.
Quantiﬁcation of IFNα activity against VSV and CSFV
Ninety-six well plates seeded with embryonic porcine kidney
(EPK) cells (for CSFV) or MDBK (for VSV) were incubated for 24 h at
37 C with the sample to be tested (swine IFN-α produced in IBRS2
cells infected with Ad5-pIFNα οr transiently transfected with
expressing plasmids inserted with porcine IFN-α genes, as well as
sera from experimental animals) diluted in two-fold series covering
a range of 1/10 to 1/20,480. Cells were then inoculated with
2000 pfu/well of vesicular stomatitis virus (VSV) (strain
NJ0612NME6) or 200 TCID50/well of CSFV strain Brescia. VSV-
infected cells were incubated for 24 h, while CSFV-infected cells
were incubated for 96 h. The IFN titer was read as the logn of the
reciprocal of the dilution in which 50% of the wells remain intact (no
cytophatic effect for VSV or lack of E2 expression detected by
immunohistochemistry for CSFV).
Quantiﬁcation of IFNα in serum
Levels of IFNα in swine sera were analyzed by MxCAT ELISA,
conventional sandwich ELISA and quantifying the anti-viral activ-
ity in cell cultures infected with VSV as previously described
(Perez-Martin et al., 2012; Moraes et al. 2003; Rubinstein et al.
1981). Brieﬂy, MDBK-t2 cells seeded into 24-well tissue culture
plates were treated with serum dilutions, and in parallel, known
amounts (from 1.95 to 1000 U/ml) of recombinant human IFNα
(PBL Assay Science, Piscataway, NJ) were applied to determine a
standard curve. Twenty-four hours later, cells were lysed and CAT
expression was determined using a commercially available ELISA
kit (Roche Applied Sciences, Indianapolis, IN) in accordance with
the manufacturer's protocol. Units of antiviral activity per ml of
the samples were calculated from the standard curve determined
with the recombinant human IFNα.
For the conventional IFN-α sandwich ELISA, two commercially
available monoclonal antibodies, K9 and F17 (PBL Assay Science),
were used for capture and detection of IFNα. Concentrations of
IFNα in serum were calculated by extrapolation in a standard
curve simultaneously determined with recombinant porcine IFNα
(PBL Assay Science). Quantiﬁcation of the sera anti-viral activity in
cell cultures infected with VSV has been previously described.
Animal studies
IFN-mediated protection experiments were performed with
commercial breed female pigs weighing 40–60 lbs. Animals were
randomly allocated into the corresponding groups following each of
the protocols. All animals were acclimated to their environment for
7 days prior to beginning each experiment. Animal experiments
were performed in accordance with protocols approved by the
Plum Island Animal Disease Center Institutional Animal Care and
Use Committee. Three groups of 5 animals each were
subcutaneously (SC) inoculated with 1010 pfu of Ad5-pIFNα–MG,
Ad5-pIFNα–D2 or Ad5-Blue empty vector. At 24 h post-Ad5 inocu-
lation all animals were intranasally challenged with 105 TCID50 of
CSFV BICv. Clinical signs and body temperature were recorded daily
throughout the experiment as previously described (Risatti et al.,
2005b). Serum samples were collected at 0 and 1 day post-
challenge (dpc) to detect levels of IFNα as well as antiviral activity,
and blood samples at 0, 4, 7, 11, 15 and 21 dpc to detect presence of
virus in blood (viremia).
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